Adenylate cyclase type 9 mRNA 3' untranslated region (ADCY9 mRNA 3'UTR)

The ADCY9 mRNA 3' untranslated region (3'UTR) is a critical regulatory segment of the messenger RNA encoding adenylate cyclase type 9, a membrane-bound enzyme that catalyzes the synthesis of cAMP from ATP (UniProt, NIH). This region serves as a hub for post-transcriptional regulation, containing multiple binding sites for microRNAs such as miR-142-3p, miR-125b, and miR-181b, which modulate ADCY9 protein expression through mRNA degradation or translational inhibition (BioRxiv, NIH). The ADCY9 gene is a prominent pharmacogenetic marker, most notably associated with the clinical efficacy of the cholesteryl ester transfer protein (CETP) inhibitor dalcetrapib (NIH, ResearchGate). Retrospective analyses of trials like dal-OUTCOMES revealed that cardiovascular outcomes and atherosclerosis progression are significantly influenced by ADCY9 polymorphisms, with the AA genotype at rs1967309 (and linked 3'UTR variants) predicting a favorable response (NIH, Karger). Beyond cardiovascular health, the 3'UTR of ADCY9 is implicated in the pathogenesis of asthma and neuropathic pain, where its regulation affects airway smooth muscle function and neuroinflammation (MDPI, NIH). Consequently, this region is an emerging target for precision medicine and the development of RNA-based therapeutics, such as siRNAs or antisense oligonucleotides, aimed at fine-tuning cAMP signaling in various disease states (ResearchGate, Frontiers).

Other names

ADCY9 3'UTRAdenylyl cyclase 9 3' untranslated regionAC9 3'UTRAdenylate cyclase type IX 3'UTR

Dalcetrapib acts as a CETP inhibitor whose clinical efficacy is modulated by ADCY9 genotype; Ritodrine is a beta-2 adrenergic agonist whose response is influenced by ADCY9 polymorphisms; endogenous microRNAs and experimental siRNAs target the 3'UTR to induce mRNA degradation or translational repression of ADCY9.